CorMedix Inc. (CRMD)

Market Cap	439.33M
Revenue (ttm)	43.47M
Net Income (ttm)	-17.93M
Shares Out	65.18M
EPS (ttm)	-0.30
PE Ratio	n/a
Forward PE	12.25
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,200,532
Open	6.62
Previous Close	6.71
Day's Range	6.31 - 6.77
52-Week Range	3.61 - 13.85
Beta	1.53
Analysts	Strong Buy
Price Target	15.14 (+124.63%)
Earnings Date	Mar 25, 2025

About CRMD

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Height...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 25, 2010
• Employees: 83
• Stock Exchange: NASDAQ
• Ticker Symbol: CRMD
• Website: https://www.cormedix.com

Analyst Forecast

According to 7 analysts, the average rating for CRMD stock is "Strong Buy." The 12-month stock price forecast is $15.14, which is an increase of 124.63% from the latest price.

Price Target

$15.14

(124.63% upside)

Analyst Consensus: Strong Buy